Company Ligand Pharmaceuticals Inc. OTC Bulletin Board

US53220K1815

Pharmaceuticals

Business Summary

Sales per Business

Sales per region

Managers

Members of the board

Share class

Shareholders

Holdings

Company contact information

Sector

Sector Other Pharmaceuticals

Inactive Instrument

End-of-day quote OTC Bulletin Board Other stock markets
- ^USD	-

27/06	Ligand Pharmaceuticals' Partner Gets US FDA Approval for Ohtuvayre to Treat Chronic Obstructive Pulmonary Disease	MT
18/06	Merck Receives FDA Approval for Capvaxive, Triggers $2 Million Payment for Ligand Pharmaceuticals	MT

Ligand Pharmaceuticals Incorporated is a biopharmaceutical company enabling scientific advancement through supporting the clinical development of medicines. The Company does this by providing financing, licensing its technologies or both. Its Captisol platform technology is a chemically modified cyclodextrin with a structure designed to optimize the solubility and stability of drugs. This technology has enabled several United States Food and Drug Administration (FDA)-approved products, including Gilead's Veklury, Amgen's Kyprolis, Baxter International's Nexterone, Melinta Therapeutics' Baxdela and Sage Therapeutics' Zulresso. Its technologies also include HepDirect, LTP and BEPro Technology Platform, SUREtechnology Platform (owned by Selexis), and Pelican Expression Technology. It has established multiple alliances, licenses and other business relationships with various pharmaceutical companies including Amgen, Merck, Pfizer, Jazz, Takeda, Gilead Sciences and Baxter International.

USD in Million	2022	Weight	2023	Weight	Delta
Biopharmaceutical 100.0 %	196	100.0 %	131	100.0 %	-33.09%

USD in Million	2022	Weight	2023	Weight	Delta
United States 100.0 %	196	100.0 %	131	100.0 %	-33.09%

Managers	Title	Age	Since
Todd Davis CEO	Chief Executive Officer	63	01/07/01
Octavio Espinoza DFI	Director of Finance/CFO	53	01/22/01
Matthew Korenberg PSD	President	49	06/15/06
Andrew Reardon LAW	General Counsel	49	01/22/01
Richard B. Baxter PRN	Corporate Officer/Principal	-	20/02
Karen Reeves PRN	Corporate Officer/Principal	-	20/02
Audrey Warfield-Graham HRO	Human Resources Officer	-	01/94/01

Members of the board	Title	Age	Since
John Kozarich CHM	Chairman	74	01/03/01
John LaMattina BRD	Director/Board Member	74	01/11/01
Stephen Sabba BRD	Director/Board Member	64	04/08/04
Jason Aryeh BRD	Director/Board Member	55	27/06/27
Todd Davis CEO	Chief Executive Officer	63	01/07/01
Nancy Gray BRD	Director/Board Member	64	18/17/18
Martine Zimmermann BRD	Director/Board Member	55	26/23/26
Jason Haas BRD	Director/Board Member	56	29/22/29

	Vote	Quantity	Free-Float	Company-owned shares	Total Float
Stock A	1	17,963,653	17,542,250 ( 97.65 %)	0	97.65 %

Name	Equities	%	Valuation
BlackRock Advisors LLC 15.16 %	2,722,594	15.16 %	232 M $
Vanguard Fiduciary Trust Co. 10.49 %	1,884,112	10.49 %	160 M $
Macquarie Investment Management Business Trust 5.752 %	1,033,181	5.752 %	88 M $
Janus Henderson Investors US LLC 5.614 %	1,008,477	5.614 %	86 M $
Stephens Investment Management Group LLC 3.879 %	696,758	3.879 %	59 M $
STATE STREET CORPORATION 3.737 %	671,284	3.737 %	57 M $
DFA Australia Ltd. 3.533 %	634,659	3.533 %	54 M $
Cardinal Capital Management LLC 3.113 %	559,235	3.113 %	48 M $
St. Denis J. Villere & Co. LLC 2.732 %	490,752	2.732 %	42 M $
Geode Capital Management LLC 2.121 %	380,970	2.121 %	32 M $

Name	Equities	%	Valuation
VIKING THERAPEUTICS, INC. 3.28%	3,616,077	3.28%	225,136,954 $

Ligand Pharmaceuticals, Inc.

555 Heritage Drive Suite 200

33458, Jupiter

+858 550 7500

http://www.ligand.com

Healthcare

Pharmaceuticals & Medical Research

Pharmaceuticals

Pharmaceuticals

Other Pharmaceuticals

	1st Jan change	Capi.
ELI LILLY AND COMPANY	+56.94%	82TCr
NOVO NORDISK A/S	+43.90%	64TCr
JOHNSON & JOHNSON	-6.77%	35TCr
MERCK & CO., INC.	+17.68%	31TCr
ABBVIE INC.	+9.70%	30TCr
ASTRAZENECA PLC	+16.08%	24TCr
ROCHE HOLDING AG	+2.29%	22TCr
NOVARTIS AG	+13.96%	22TCr
AMGEN INC.	+7.93%	17TCr

Other Pharmaceuticals